| abstract |
The present invention relates to an integrin expression inhibitor, an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, based on an integrin inhibitory activity of an anticoagulant or anti-cancer agent. In particular, the present invention relates to an integrin expression inhibitor comprising a sulfonamide compound of formula (I), a pharmaceutically acceptable salt or hydrate thereof, as an active ingredient. In the formula B is a C 6 -C 10 aryl ring or a 6 to 10-membered heteroaryl ring which may have a substituent and wherein part of the ring may be saturated, K is a single bond, CH = CH- or - (CR 4bR 5b) mb (wherein R 4b and R5b is the same or different and is each hydrogen or (C1-C4) alkyl, and mb is an integer of 1 or 2), R1 is hydrogen or (C1-C6) -alkyl, Z is a single bond or -CO-NH-, and R is 6 An aryl ring of 10 carbon atoms or a 6-10 membered heteroaryl ring which may have a substituent and in which a portion of the ring may be cleaved. SHE |